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Abstract
Background: Control of lymphatic filariasis (LF) in most of the sub-Saharan African countries is based on annual
mass drug administration (MDA) using a combination of ivermectin and albendazole. Monitoring the impact of this
intervention is crucial for measuring the success of the LF elimination programmes. This study assessed the status
of LF infection in Rufiji district, southeastern Tanzania after twelve rounds of MDA.
Methods: Community members aged between 10 and 79 years were examined for Wuchereria bancrofti circulating
filarial antigens (CFA) using immunochromatographic test cards (ICTs) and antigen-positive individuals were screened for
microfilaraemia. All study participants were examined for clinical manifestation of LF and interviewed for drug uptake
during MDA rounds. Filarial mosquito vectors were collected indoor and outdoor and examined for infection with
W. bancrofti using a microscope and quantitative real-time polymerase chain reaction (qPCR) techniques.
Results: Out of 854 participants tested, nine (1.1%) were positive for CFA and one (0.1%) was found to be microfilaraemic.
The prevalence of hydrocele and elephantiasis was 4.8% and 2.9%, respectively. Surveyed drug uptake rates were high,
with 70.5% of the respondents reporting having swallowed the drugs in the 2014 MDA round (about seven months
before this study). Further, 82.7% of the respondents reported having swallowed the drugs at least once since the
inception of MDA programme in 2000. Of the 1054 filarial vectors caught indoors and dissected to detect W. bancrofti
infection none was found to be infected. Moreover, analysis by qPCR of 1092 pools of gravid Culex quinquefasciatus
collected outdoors resulted in an estimated infection rate of 0.1%. None of the filarial vectors tested with qPCR were
found to be infective.
Conclusion: Analysis of indices of LF infection in the human population and filarial mosquito vectors indicated a
substantial decline in the prevalence of LF and other transmission indices, suggesting that local transmission was
extremely low if occurring at all in the study areas. We, therefore, recommend a formal transmission assessment
survey (TAS) to be conducted in the study areas to make an informed decision on whether Rufiji District satisfied
WHO criteria for stopping MDA.
Keywords: Lymphatic filariasis, Mass drug administration, Microfilaremia, Circulating filarial antigens, Hydrocele,
Elephantiasis, Wuchereria bancrofti, Tanzania
* Correspondence: clarajones2003@yahoo.co.uk
1Department of Parasitology and Medical Entomology, Muhimbili University
of Health and Allied Sciences, P. O. Box 65011, Dar es Salaam, Tanzania
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jones et al. Parasites & Vectors          (2018) 11:588 
https://doi.org/10.1186/s13071-018-3156-2
Background
Lymphatic filariasis (LF) is the second most common
vector-borne parasitic disease after malaria and is found
in over 83 tropical and subtropical countries [1]. It is es-
timated that one billion people are at risk of infection
and 120 million are affected by LF. Of those at risk of
infection, 65% reside in the Southeast Asia, 30% in Africa,
and the remainder live in other parts of the tropical world
[2, 3]. In sub-Saharan Africa, LF is caused by infection
with the parasitic nematode Wuchereria bancrofti and
transmitted by night-biting mosquitoes of the genera
Anopheles and Culex [4]. The most important filarial vec-
tors in sub-Saharan Africa are Culex quinquefasciatus
(widespread in urban and semi-urban areas) and members
of the Anopheles gambiae complex and An. funestus group
found in rural areas [5].
In 1997, the World Health Assembly passed a resolution
calling for the elimination of LF as a public health prob-
lem globally [6, 7]. As a result, the Global Programme to
Eliminate Lymphatic Filariasis (GPELF) was launched
in 2000 by the World Health Organization (WHO).
The programme had a principle objective of interrupt-
ing the transmission of W. bancrofti and Brugia malayi
through the application of annual mass drug adminis-
tration (MDA) to the entire at-risk population as well
as management and prevention of LF-related disabil-
ities [8]. The fundamental assumption behind the MDA
approach is that once the community has been treated
long enough, levels of microfilariae will remain below
that required to sustain transmission [9]. It has been
suggested that after four to six consecutive rounds of
MDA, microfilariae load in the endemic population is
expected to fall below 1%, and this reduction in micro-
filaraemia will lead to the reduced acquisition of new
infections [10].
LF is endemic in many parts of mainland Tanzania
where nearly 70% of the population is at risk, and six
million people are estimated to have disabilities due to
the disease [11]. LF endemicity varies across the country,
with high antigenemia levels of 45–60% along the coast
to 2–4% in western Tanzania [11]. Tanzania was one of
the first countries in sub-Saharan Africa to adopt the
WHO recommended strategy of applying annual MDA
to eliminate LF, and the Tanzanian National Lymphatic
Filariasis Elimination Programme (NLFEP) was launched
on Mafia Island in 2000 [12]. Since then, the programme
has expanded to cover a total population of 13 million
people treated at least once with ivermectin and albenda-
zole, with a target to extend the coverage to the entire esti-
mated at-risk population of around 34 million people [11].
Monitoring of the transmission dynamics during MDA
implementation is essential for measuring the progress
and defining MDA endpoints. The main measures used to
assess the impact of LF MDA have relied upon detection of
parasites, parasite antigens, parasite DNA and/or anti-para-
site antibodies in humans [13]. However, detecting
these indicators of LF infection in humans are not
always definitive of local transmission as they may not
account for immigration of infected individuals to areas
where transmission has been controlled [13]. On the
other hand, detection of filarial parasites in mosquito
vectors indicates infection uptake from human hosts
while the presence of infective third-stage larvae (L3)
indicates a possibility of local transmission [14, 15].
Thus, monitoring W. bancrofti infection in humans to-
gether with vector infectivity provides a more sensitive
measure of local transmission. The present study moni-
tored W. bancrofti infection status of the human popu-
lation and mosquito vectors after twelve annual rounds
of MDA with a combination of ivermectin (150–200
mg/kg) and albendazole (400 mg) delivered to individ-
uals aged five years and above in the highly endemic
area of southeastern Tanzania.
Methods
Study area
This study was conducted in Rufiji District (7°57'S, 38°
43'E) southeastern Tanzania about 150 km south of Dar
es Salaam. Based on 2012 census data, the district had a
total population of 217,274 people [16]. The district lies
within the floodplain of Rufiji River, c.500 m above sea
level. The district has two main rain seasons; a long
rainy season between February and May and a shorter
less intense one from October to December. The annual
rainfall ranges between 800–1000 mm. Rufiji District
was purposively selected for the study due to its history
of high LF prevalence before the start of elimination
activities based on ivermectin and albendazole MDA in
2002. Twelve rounds of annual MDA were completed in
Rufiji District between 2002 and 2014 (Table 1).
The district has a total of 83 registered villages across
19 administrative wards. Using stratified random sampling,
five villages (Bungu, Nyambili, Nyanjati, Mchukwi and
Nyamisati) were selected for the study representing three
main ecological settings of the district. Nyamisati is located
along the coast of the Indian Ocean while both Bungu and
Nyanjati are inland villages with high and low population,
respectively. Nyambili is a lowland village at the basin of
Rufiji River prone to flooding during the rainy season, and
Mchukwi is a relatively highland village. Before MDA in
2000, the prevalence of W. bancrofti circulating filarial anti-
gens (detected using immunochromatographic test (ICT)
cards), microfilaraemia, hydrocele, and elephantiasis were
49, 18, 12 and 4%, respectively (Tanzanian Ministry of
Health and Social Welfare (MoHSW) 2000, unpublished).
The present study was conducted in April 2015, about
seven months after the 12th annual round of MDA based
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on a combination of ivermectin and albendazole delivered
in September 2014.
Study population and sampling
Study participants were selected from a list of names of
heads of households obtained from the respective village
executive officers. Forty heads of households were ran-
domly selected from the list, and all members of the
household included for the survey. In 2012, the average
household size in Rufiji was reported to be five individuals
[16], and thus it was estimated to screen 200 individuals
from each village. On the survey date, participants were
invited to a central place (dispensary or school premises)
for blood testing and interviews. Participants who did not
turn up for screening in the central place were followed at
their homes.
LF prevalence, burden and MDA compliance
Consented community members aged between 10 and
79 years) in the study villages were examined for W.
bancrofti CFA using immunochromatographic test (ICT)
cards (Binax Now® Filariasis, Inverness Medical Innovations
Inc., Massachusetts, USA) following the manufacturer’s in-
structions. Briefly, 100 μl of finger-prick blood was collected
from each participant and applied to the test card. Test re-
sults were read after precisely 10 min as positive, negative
or undetermined. All CFA positive cases detected during
the daytime were further examined for microfilaria (MF) by
using counting chamber technique [17]. For MF testing,
100 μl of finger-prick blood was collected with sterile
heparinised capillary tubes starting from 22:00 to 00:00 h
and transferred to sample tubes with 900 μl of 3% acetic
acid. In the laboratory, the samples were transferred into
the counting chamber and examined for MF under a com-
pound microscope. Moreover, participants were examined
in privacy by the study clinicians for clinical manifestation
of LF. Using pre-designed forms, demographic information
such as sex, age, marital status, occupation, and duration of
residence in Rufiji were recorded for all participants. More-
over, participants were interviewed on whether they had
swallowed ivermectin and albendazole distributed in the
community in September 2014 and also their participation
in drug uptake in any of the previous 12 annual MDA
campaigns.
Vector and transmission surveys
Filarial mosquito vectors were collected from 10 selected
houses from each village using Centre for Disease Control
(CDC) light traps (John W. Hock Company, Gainesville,
USA). To optimize trap yield, households with thatched
roof and open eaves were selected from different parts of
each of the trapping village in a non-random approach.
Sleeping rooms with a bed and a willing occupant was
selected for trapping. CDC light trap was placed beside an
occupied bed (with occupant protected with a long-lasting
insecticide-treated net) in each household for two con-
secutive nights. Light traps were switched on between
17:00 and 18:00 h and then turned off between 06:00 and
07:00 h the following morning. Mosquitoes collected from
each light trap type were transferred separately into
labeled paper cups covered with a netting material and
offered cotton pads soaked in a 10% glucose solution
and transported to the field laboratory. In the labora-
tory, they were knocked down with chloroform, sorted,
and then identified based on morphological characters.
Freshly-killed female filarial mosquito vectors were dis-
sected and examined under a microscope for parity and
infection with W. bancrofti as described previously [18].
CDC gravid traps were also set outdoors (in the same
households used for setting a light trap) to collect gravid
mosquitoes for two consecutive nights in each house.
The traps were set in peri-domestic areas, and the trap-
pings were conducted as described by Irish et al. [19]. In
brief, the traps were switched on between 17:00 and
18:00 h and switched off the next morning between
06:00 and 7:00 h. Collected mosquitoes were treated as
described for light trap catch except that the filarial vec-
tors from gravid traps were preserved individually in
Eppendorf tubes containing silica gel desiccants for later
detection of infection using the quantitative real-time
polymerase chain reaction (qPCR) technique.
For qPCR processing, gravid Cx. quinquefasciatus were
dissected to separate head, thorax, and abdomen. Com-
bined thorax and abdomen segments were processed
separately from the heads in pools of five mosquitoes.
DNA was extracted from pooled mosquito segments by
using the Livak method [20]. In brief, mosquitoes were
Table 1 Reported treatment coverage during ivermectin and
albendazole MDA intervention in Rufiji District, southeastern Tanzania
MDA No. Treatment year Target population Treated population
(% coverage)
1 2002 138,370 75,135 (54.3)
2 2003 141,628 123,216 (87.0)
3 2004 144,962 136,267 (94.0)
2005a – –
4 2006 151,868 85,046 (56.0)
5 2007 155,443 116,583 (75.0)
6 2008 159,103 115,350 (72.5)
7 2009 162,848 130,279 (80.0)
8 2010 166,682 113,677 (68.2)
9 2011 170,606 150,133 (88.0)
10 2012 236,614 146,060 (61.7)
11 2013 243,835 149,163 (61.2)
12 2014 217,274 168,930 (77.7)
aMDA was not implemented in 2005
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homogenized in Livak buffer (0.5% sodium dodecyl
sulphate (SDS), 0.08M sodium chloride (NaCl), 0.16M su-
crose, 0.5M ethylenediaminetetraacetic acid (EDTA) and
0.12M Tris-HCl), proteins and debris separated with 8M
potassium acetate, and DNA precipitated with ethanol.
The resultant DNA was rinsed in 70% cold ethanol, dried
and re-suspended in tris-acetate-EDTA (TAE) buffer.
An aliquot of extracted DNA from heads was combined
with those from the thorax and abdomen segments and
screened in the initial qPCR run to detect infection
with W. bancrofti. After that, the heads of the positive
pools were re-tested in the follow-up qPCR screening
to establish whether the positive signal from the initial
qPCR run was obtained from the head segment.
The extracted DNA was analysed for the presence of
W. bancrofti DNA by qPCR using the method of Rao et
al. [15]. In brief, the long DNA repeat (LDR) of W. ban-
crofti was targeted with specific forward and reverse
primers (LDR1 and LDR2) and TaqMan probe for amplifi-
cation and detection. In the reaction mixture, each 10 μl
of PCR consisted of 0.5 μM of each of the two primers
(LDR1 and LDR2), 12.5 μl of TaqMan probe (Applied
Biosystems, Foster City, CA, USA), 1:1 SensiMix™
(Bioline, Meridian Bioscience Asia Pte Ltd, Queenstown,
Singapore) and 1 μl of DNA extract. Thermal cycling con-
ditions included 95 °C for 10 min followed by 40 cycles of
denaturation at 92 °C for 15 s and annealing at 60 °C for
60 s. Each batch of samples was run with positive and
negative controls. Thermal cycling and sample analysis
were performed with Agilent MX 3005P qPCR systems,
with MXPro software (5301 Stevens Creek Blvd, Santa
Clara, CA 95051, USA).
Data analysis
Data were entered in Excel spreadsheets (Microsoft Corp.,
Redmond, WA, USA) and subsequently analyzed with
SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA). Blood
test results for CFA and MF, the presence of hydrocele or
elephantiasis, demographic characteristics, and MDA
compliance were compared by using the Chi-square test
and P-values ≤ 0.05 were considered statistically signifi-
cant. The lower and upper limits of the 95% confidence
interval for the prevalence of MF and CFA were calculated
according to the method described by Newcombe [21].
For pool screening qPCR, the probability that any one
mosquito in the pool was infected with W. bancrofti was
estimated by pool-screen v2.0.2 software providing max-
imum likelihood estimates for infection rates as previously
described [22].
Results
LF prevalence and disease burden
A total of 854 individuals above five years-old in five
villages of Rufiji District were examined for CFA, MF,
hydrocele and elephantiasis. The overall male to female
ratio was 1.3, and the mean age of the participants was
32.3 years (range of 10–79 years). Of 854 individuals
screened for LF infection, 9 (1.1%) and 1 (0.1%) had CFA
and MF, respectively (Table 2). Males were significantly
more infected (CFA) than females (χ2 = 3.921, df = 1, P =
0.048). Of the 48 individuals found with the chronic clin-
ical manifestation of LF, 23/481 (4.8%) and 25/854 (2.9%)
had hydrocele and elephantiasis, respectively (Table 2).
None of the individuals with hydrocele or elephantiasis
were found to have MF or CFA.
LF transmission indices
A total of 3334 mosquitoes were caught using CDC light
traps of which 69 (2.1%) were identified as species of the
Anopheles gambiae complex, 1054 (31.6%) were Culex
quinquefasciatus, and 2211 (66.3 %) were non-filarial vec-
tor species. In the laboratory, filarial mosquito vectors
were dissected for parity, and 558 parous vectors were ex-
amined under microscopy for infection with W. bancrofti.
None of the mosquitoes examined for infection was found
to carry W. bancrofti larvae of any stage (Table 3).
A total of 5460 gravid Cx. quinquefasciatus were col-
lected outdoors using CDC gravid traps and dissected to
separate head, thorax and abdomen. An aliquot of DNA
from the head, thorax and abdomen of the 5460 Cx.
quinquefasciatus was tested in pools of five mosquitoes
(a total of 1092 pools) with qPCR. Of 1092 pools of Cx.
quinquefasciatus tested, five pools were positive for W.
bancrofti DNA. Further analysis by pool screen (v2.0.2
software) gave an estimate that 0.1% of the tested mos-
quitoes were infected (Table 3). Further analysis of an
aliquot of DNA from head segments of the infected
pools revealed the absence of infective mosquitoes (i.e.
mosquitoes harboring third-stage larvae of W. bancrofti).
MDA compliance concerning LF infection status
Of the 854 individuals interviewed, 82.4% reported hav-
ing participated in at least one previous MDA round,
while 70.6% participated in an MDA that was conducted
in September 2014 (about seven months before the
present study). Individuals who did not participate in
any of the previous rounds of MDA were significantly
more infected (CFA) compared with those with a recent
history of participating in MDA (χ2 = 8.723, df = 1, P =
0.003). The proportion of males with hydrocele was sig-
nificantly higher in individuals who did not swallow
drugs in any MDA round while the prevalence of ele-
phantiasis was not significantly different between these
two groups of participants (Table 4).
Discussion
LF elimination activities based on annual MDA with a
combination of ivermectin and albendazole have been
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ongoing in Tanzania for more than a decade. Thus,
regular monitoring is essential to evaluate the progress
and make informed decisions on when it is safe to stop
MDA intervention. Studies on the impact of MDA on
LF transmission and infection in areas implementing
diethylcarbamazine (DEC) and albendazole regimes such
as American Samoa, India, Egypt and Papua New Guinea,
have documented good progress towards elimination
[23–25]. In sub-Saharan Africa, many LF-endemic coun-
tries are co-endemic with onchocerciasis and thus ivermec-
tin is used to avoid the potential DEC-induced side effects
on onchocerciasis patients. Using a combination of iver-
mectin and albendazole MDA strategy, some West African
countries are showing good progress toward elimination of
LF [26, 27], and Togo has been declared to have achieved
LF elimination target [28, 29]. In northeastern Tanzania,
the impact of MDA with this drug combination has shown
a remarkable decline in LF infection and transmission [30].
The documented declining trend in LF transmission sug-
gests the need to conduct a WHO-approved transmission
assessment survey (TAS) to determine whether MDA can
be stopped in endemic areas showing good progress.
The findings of this study have shown that after 12
rounds of ivermectin and albendazole MDA in the Rufiji
District there has been a progressive decline in LF preva-
lence and transmission since the start of MDA interven-
tion in 2002. Before the MDA intervention, the prevalence
of CFA, MF, hydrocele and elephantiasis was 49%, 18%,
12% and 4%, respectively (MoH 2000, unpublished). In
this study, no children tested positive for CFA in 2015 sur-
veys (after 12 rounds of MDA). This shows a significant
decline in CFA rates compared to our previous findings in
the same study area in 2012 (after 9 MDA rounds), which
showed CFA rate of 14.3% among pupils screened [31].
This decline in CFA suggests a substantial reduction in
the acquisition of new infection in children from 2012 to
2014. The prevalence of MF and CFA recorded in the
current study (0.1% and 1.1%, respectively) were below the
WHO-recommended elimination thresholds of 1% (for
MF) and 2% (for CFA) [3]. Our findings on the decline of
Table 2 Prevalence of CFA, microfilariae and clinical manifestation of lymphatic filariasis infection by gender, age and village
location in Rufiji District, southeastern Tanzania
Characteristic No. (%) examined No. (%) with CFA
[95% CI]
No. (%) with MF
[95% CI]
No. (%) with hydrocelea No. (%) with elephantiasis
Gender
Male 481 (56.3) 8 (1.7) [0.8–3.2] 1 (0.2) [0.0–1.2] 23 (4.8) 18 (3.7)
Female 373 (43.7) 1 (0.3) [0.1–1.5] 0 (0.0) [0.0–1.0] – 7 (1.9)
Total 854 9 (1.1) [0.6–2.0] 1 (0.1) [0.0–0.7] 23 (4.8) 25 (2.9)
Age (years)
5–14 188 (22.1) 1 (0.5) [0.1–3.0] 0 (0.0) [0.0–2.0] 0 (0.0) 1 (1.0)
15–34 307 (35.9) 4 (1.3) [0.5–3.3] 1 (0.3) [0.1–1.8] 8 (4.7) 13 (7.8)
≥ 35 359 (42.0) 4 (1.1) [0.4–2.8] 0 (0.0) [0.0–1.1] 15 (7.0) 11 (5.2)
Total 854 9 (1.1) [0.6–2.0] 1 (0.1) [0.0–0.7] 23 (4.8) 25 (2.9)
Village
Nyamisati 213 (24.9) 0 (0.0) [0.0–1.8] 0 (0.0) [0.0–1.8] 7 (4.1) 5 (2.3)
Nyambili 196 (23.0) 6 (3.1) [1.4–6.5] 1 (0.5) [0.1–2.8] 5 (5.0) 10 (5.1)
Nyanjati 189 (22.1) 0 (0.0) [0.0–2.0] 0 (0.0) [0.0–2.0] 3 (3.6) 7 (4.1)
Bungu 172 (20.1) 3 (1.7) [0.6–5.0] 0 (0.0) [0.0–2.2] 4 (5.1) 3 (1.7)
Mchukwi 84 (9.8) 0 (0.0) [0.0–4.4] 0 (0.0) [0.0–4.4] 4 (8.3) 0 (0.0)
Total 854 9 (1.1) [0.6–2.0] 1 (0.1) [0.0–0.7] 23 (4.8) 25 (2.9)
aDenominator included only males
Table 3 Filarial mosquito vectors caught and analyzed for infection and or/infectivity with W. bancrofti using microscopy and qPCR
Collection method Vector collected Parous vectors Method of analysis No. analyzed No. infected (%) No. infective (%)
Light trap 1123a 558b Microscopy 558 0 (0) 0 (0)
Gravid trap 5460 – qPCR 1092c 5 (0.1)d 0 (0)
aFilarial vector composition: Anopheles gambiae complex (n = 69) and Culex quinquefasciatus (n = 1054)
bParous vectors: An. gambiae complex (n = 45) and Cx. quinquefasciatus (n = 513)
cPools of 5 Cx. quinquefasciatus each
dInfection rate (Pool Screen V2.0.2; Likelihood ratio method; 95% CI: 0.03–0.22%)
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LF infection and transmission due to MDA intervention
corroborate those reported by Simonsen et al. [30] in
northeastern Tanzania.
Detection of W. bancrofti infection in mosquito vectors
is an essential aspect of monitoring LF transmission as it
provides real-time information on the presence of local
transmission [14]. CDC light and gravid traps have been
considered efficient tools for the collection of filarial vec-
tors in areas where Anopheles and Cx. quinquefasciatus
are the primary vectors [32]. Important filarial mosquito
vectors found elsewhere in Tanzania, such as the species
of the An. gambiae complex, An. funestus group and Cx.
quinquefasciatus have also been reported in Rufiji District
[33]. In this study, none of the dissected filarial vectors
examined for infection (Cx. quinquefasciatus and An.
gambiae complex) were found to carry W. bancrofti larvae
of any stage. Using qPCR with high throughput and preci-
sion, the probability of finding an infected mosquito in
any of the analysed pools of gravid Cx. quinquefasciatus
was estimated at 0.1%. Importantly in the transmission,
none of the mosquitoes tested with qPCR was found to
carry an infective stage of W. bancrofti. The fact that we
did not identify any LF-infective vector by either qPCR or
dissection suggests that local transmission is extremely
low if occurring at all in the study areas.
The present study showed that the prevalence of
hydrocele and elephantiasis was lower than that reported
by the MOH before MDA (MoHSW 2000, unpublished),
but the survey methods differed and a statistical compari-
son of prevalence in the two studies could not be made. In
contrast, the proportion of individuals with elephantiasis in
the present study was similar to that reported by Gasarasi
et al. [34] who conducted a study in the same area in 2000.
Other studies conducted elsewhere have indicated a
moderate to no reduction in the prevalence of lym-
phoedema after several rounds of MDA [35, 36]. There-
fore, the observed low rate of hydrocele in this study
might be explained by the ongoing hydrocelectomy inter-
vention in the district.
Treatment coverage and compliance are crucial factors to
observe when assessing the impact of MDA on LF trans-
mission. For MDA strategy to be effective, sustained high
treatment coverage is critical to reach the elimination target
within a reasonable time-frame [37]. Moreover, empirical
evidence suggested that endemic areas with high baseline
infection levels will require higher treatment coverage and
a more sustained MDA intervention [38]. However, it has
been documented that attaining optimal drug uptake
during MDA is a challenge in LF control programmes in
most of the endemic areas [39–41]. In this study, the sur-
veyed drug uptake was 70.6 and 82.4% for the last MDA
round (September 2014, seven months before the present
study) and participation in any previous MDA rounds, re-
spectively. The surveyed MDA coverage in our study was
at the recommended range of 60–70% drug uptake rates
required for interruption of transmission [37]. Although
drug uptake was found to be significantly lower in respon-
dents with hydrocele, previous studies have reported a low
prevalence of microfilaraemia in individuals with hydrocele
and elephantiasis [42, 43].
Our study has recorded a progressive and substantial
decline in LF prevalence in the study areas when com-
pared to the baseline values before MDA and also to a
more recent survey conducted in the same villages in
2012 [31]. In addition to the impact of MDA, the universal
distribution of long-lasting insecticide-treated nets which
Table 4 Demographic characteristics of the study population and their reported drug uptake in relation to their LF infection status
Characteristic No. (%) of total No. (%) with CFA χ2-value
(P-value)
No (%)a with
hydrocele
χ2-value
(P-value)
No (%) with
elephantiasis
χ2-value
(P-value)
Gender (n = 854)
Males 481 (56.3) 8 (1.6) 3.921 (0.048) 23 (4.8) – 18 (3.7) 2.573 (0.109)
Females 373 (43.7) 1 (0.3) 7 ( 1.9)
Age groups in years (n = 854)
≤ 29 450 (52.7) 4 (0.9) 0.248 (0.618) 5 (2.0) 8.723 (0.003) 13 (2.9) 0.005 (0.944)
≥ 30 404 (47.3) 5 (1.2) 18 (7.8) 12 (3.0)
Reported drug uptake in previous MDAs (n = 854)
Yes 704 (82.4) 4 (0.6) 8.723 (0.003) 9 (2.4) 22.743 (0.001) 19 (2.7) 0.737 (0.391)
No 150 (17.6) 5 (3.3) 14 (13.7) 6 (4.0)
Reported drug uptake in 2014 MDA (n = 854)
Yes 603 (70.6) 6 (1.0) 0.068 (0.794) 8 (2.5) 10.243 (0.001) 16 (2.7) 0.542 (0.462)
No 251 (29.4) 3 (1.2) 15 (9.1) 9 (3.6)
aDenominator included only males: for age group ≤ 29 and ≥ 30 there were 249 and 232 males; drug uptake in any previous MDA, 379 males swallowed the
drugs while 102 did not swallow the drugs; drug uptake in 2014 MDA, 316 males swallowed the drugs while 165 did not
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was implemented in 2012 could contribute to the drastic
decline in LF disease prevalence. Insecticide-treated nets
distributed for malaria control have been shown to reduce
LF prevalence in some settings [44–47].
Despite a substantial decline in LF in this study areas,
a recommendation to stop MDA could not be made
because the current study methods did not follow
WHO-approved TAS. The design of the present study
was adopted as a result of limited funding and time to
implement an elaborated WHO-approved TAS protocol.
Moreover, the direct statistical comparison between the
baseline study in 2000 and the present study could not be
made due to the unavailability of a detailed methodology
for the baseline study. With these limitations, it is advis-
able that a formal TAS is conducted before MDA can be
stopped the area.
Conclusions
Analysis of indices of LF infection in the human popula-
tion and filarial mosquito vectors demonstrated a sub-
stantial decline in the prevalence of LF in the study
areas when compared with baseline values before the
start of elimination activities based on MDA. We recom-
mend a formal TAS to be conducted in the study areas
to make an informed decision on whether MDA can be
stopped in Rufiji District.
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